Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
- Status
- TERMINATED
- Phase
- PHASE1
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
- Status
- COMPLETED
- Phase
- PHASE2
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
- Status
- UNKNOWN
- Phase
- PHASE2
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
- Status
- COMPLETED
- Phase
- NA
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Infliximab in Treating Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2